Northway Biotech
WALTHAM, MA / ACCESSWIRE / May 24, 2023 / Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant, state-of-the-art cGMP manufacturing site in Vilnius, Lithuania, announced the completion of its expansion project for cGMP manufacturing facilities in Waltham, Massachusetts. This significant accomplishment further solidifies Northway Biotech's standing as an influential player in the global biopharmaceutical landscape.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.This recent growth is an extension of the successful launch of Northway Biotech's process and analytical development laboratories in Waltham (Greater Boston area) in 2020. The expanded facility now includes state-of-the-art cGMP suites, marking a significant milestone in the company's journey. The newly established cutting-edge biomanufacturing suites host a microbial fermentation train with up to 450 liters of volume capacity, and a mammalian production train with the ability to handle volumes of up to 2,000 liters. Northway Biotech has further established a specialized, fully automated fill and finish line to accommodate its clients' varied needs, supporting high-throughput filling into vials, syringes, and cartridges.
Prof. Vladas Algirdas Bumelis, CEO of Northway Biotech, shared his insights regarding this accomplishment, stating, "The addition of GMP suites in our US site represents a transformative step for our organization, enabling us to provide comprehensive end-to-end solutions from our second site now. We are poised to transition current process development projects into the cGMP manufacturing phase in a timely manner, in line with our clients' committed schedules. Additionally, our longstanding US partners who have engaged with our Lithuanian site can now also take advantage of the geographical convenience of our modern facilities located in the Greater Boston Area. With our fully functional and technologically advanced manufacturing site at our disposal, Northway Biotech is perfectly positioned to take on manufacturing projects aimed at both clinical and commercial supply."
To commemorate this significant expansion and express gratitude to its valued partners and industry leaders, Northway Biotech will be hosting a grand opening event for its cGMP suites on June 8. This event promises to be an occasion of celebration and networking, providing an opportunity for attendees to witness firsthand the state-of-the-art facilities and engage in meaningful discussions within the biotech community.
About Northway Biotech - https://www.northwaybiotech.com
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately-owned company founded in 2004 and located in Vilnius, Lithuania; London, United Kingdom; and Waltham, Massachusetts, United States.
For Further Information, Contact:
Prof. Vladas Algirdas Bumelis
CEO and Chairman of the Board
Northway Biotech
vladas.bumelis@northwaybiotech.com
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/757061/Northway-Biotech-Set-to-Launch-Advanced-Microbial-and-Mammalian-GMP-Facilities-in-Massachusetts
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
A New Shade of Comfort: LiberNovo Omni Debuts New Moss Green Design6.1.2026 08:10:00 CET | Press release
HONG KONG, HK / ACCESS Newswire / January 6, 2026 / LiberNovo The pioneer of dynamic ergonomic seating today announced the upcoming Moss Green variant of its flagship chair, the LiberNovo Omni , launching in Europe on January 17, 2026 (CET) . Building on the success of Midnight Black and Space Grey, Moss Green introduces a nature-inspired palette paired with a softer, upgraded fabric designed for long-hour comfort. As hybrid work becomes the norm across Europe, professionals increasingly seek seating that integrates seamlessly into home environments while supporting extended periods of task switching. Moss Green offers a warm, understated aesthetic that blends naturally into modern workspaces. The new colorway retains the LiberNovo Omni's full Dynamic Support system, providing adaptive support whether users are deeply focused, shifting between tasks, or relaxing after long sessions. A Calming Revival of Nature, Designed for Modern Work Inspired by forest moss, the Moss Green tone blend
Datavault AI and Available Infrastructure to Scale Physical Private Edge Cloud to Deliver Powerful Zero Trust Cybersecurity, Digital Twin and Agentic Data Monetization to 100 U.S. Cities in 20265.1.2026 14:07:00 CET | Press release
Partnership pairs Datavault AI's patented DataValue®, DataScore® and Information Data Exchange® (IDE®) solutions with Available Infrastructure's SanQtum™ cybersecure high performance points of presence designed to support near-real-time tokenization, data exchange, and agentic monetization that will provide Datavault AI the foundation to scale enterprise adoption of its AI while also solving for requisite regulatory compliance for its IDE® Quantum Key Encryption from SanQtum will further differentiate patented and forthcoming Datavault AI IDE deployments with Elements Exchange (RWA), NIL and American Political Exchanges set to Launch Q1 2026, that will be quantum ready 33 Top cities in US will begin with systems integration of patented Data Vault, DataScore, IDE and Available Infrastructure's SanQtum cybersecurity for private high performance computing in the Datavault AI Edge Network PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 5, 2026 / Datavault AI ("Datavault AI" or the "
Datavault AI and The Dream Bowl to Set New Benchmark in Sports Innovation with World’s First Tokenized Autograph Session, Featuring Current and Future NFL Stars - Live on ESPN+2.1.2026 19:50:00 CET | Press release
30 former NFL star players from different NFL Teams will autograph on-site up to 3,000 The Dream Bowl memorabilia items such as helmets, footballs, jerseys, and live-autographs by Notable Live. Autographed memorabilia items will be anchored by Prova & Sumerian technologies and digital twins will be tokenized with Data Vault. Digital tokens anchored to real The Dream Bowl autographed memorabilia items will be awarded [by lottery] to holders of the original Dream Bowl Meme Coin token (the "Dream Bowl Meme Coin I") and, following the distribution date of the Dream Bowl Meme Coin II tokens to certain record holders of Datavault AI securities as of January 7, 2026 (the "Dream Bowl Meme Coin II" and together with the Dream Bowl Meme Coin I, the "Dream Bowl Meme Coins"), to holders of the Dream Bowl Meme Coin II, throughout 2026 with an average of 10 winners selected every business day. Dream Bowl Meme Coins memorabilia digital tokens will be traded on Datavault AI's forthcoming International
Clean Air Metals Files Interim Financial Statements for the Nine Months Ended October 31, 202530.12.2025 03:20:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / December 29, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the nine-month period ended October 31, 2025, available for viewing on www.sedarplus.ca. Financial Highlights Total assets as at October 31, 2025 of $36,602,553 Total cash as at October 31, 2025 of $1,643,422 Working capital deficiency as at October 31, 2025 of $1,746,454 Shareholder's equity as at October 31, 2025 of $33,030,843 During the nine months ended October 31, 2025, the Company incurred $1,046,223 in cost for exploration activities at the TBN project. Key activities of the Company's management team this quarter included the completion of the initial drilling of the first step-out exploration target within the Escape down-plunge area, resulting in a mineralized intersection 400m from the known resource.
EESystem Files for Preliminary Injunction to Block Unauthorized Use of Proprietary Wellness Technology29.12.2025 17:15:00 CET | Press release
Legal action seeks to halt Jason Shurka and The Light System, Inc. from misappropriating EES intellectual property LAS VEGAS, NV / ACCESS Newswire / December 29, 2025 / Energy Enhancement System, LLC (EES), a global provider of advanced wellness technology, has taken decisive legal action to protect its proprietary innovations and the integrity of its licensed network. On December 22, 2025, EES filed a Motion for Preliminary Injunction in the U.S. District Court for the District of Nevada. The motion seeks to immediately enjoin defendants Jason Shurka and The Light System, Inc., operating via thelightsystems.com and unifydhealing.com, with events and personal bio promoted on jasonshurka.com, from the unauthorized use of EES's intellectual property. This filing is a critical step in defending the authenticity of the EE System technology, which powers an extensive global network with thousands of installations worldwide. The motion is supported by detailed evidence alleging contractual b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom